ST6GAL1 and hepatocellular carcinoma: Notably, among HCC patients with high serum ST6GAL1 levels who received tyrosine kinase inhibitors (TKI) therapy, lenvatinib conferred better survival than sorafenib [89], implying that detection of serum ST6GAL1 is useful in guiding the selection of appropriate drug therapy for HCC patients.